The utility of blood-based biomarkers for Alzheimer*s disease in memory Clinic
Completed
- Conditions
- cognitieve impairmentDementia10011305
- Registration Number
- NL-OMON51700
- Lead Sponsor
- Medisch Centrum Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 400
Inclusion Criteria
The patient has to have cognitive complaints or behavioral change and has to be
referred from the GP to the memory clinic.
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
1) age under 50
2) known alcohol abuse in the past or present
3) Incapacitated patients
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main outcome measure is:<br /><br>1) Agreement will be calculated between plasma biomarkers for AD and clinical<br /><br>diagnosis at baseline and at follow up (1 year).<br /><br><br /><br>Working diagnosis<br /><br>Diagnoses of probable AD will be made according to the core clinical criteria<br /><br>of the National Institute on Aging-Alzheimer*s Association (NIA-AA) workgroups.<br /><br></p><br>
- Secondary Outcome Measures
Name Time Method <p>Information for descriptive statistics, if present, will be collected (Disease<br /><br>stage, reported cognitive complains, impairment daily living, cranial MRI<br /><br>result and CSF results). There are no other secondary outcomes. </p><br>